engleski

Effectivness of treatment with risperidone solution in patients with schizophrenia and patients with bipolar disorder

Background was to measure symptomatic changes with the BPRS and the CGI in patients with paranoid schizophrenia and patients with bipolar disorder type I taking risperidone solution. BPRS and CGI were used in order to measure symptomatic changes in 30 patients with paranoid schizophrenia and 30 patients with bipolar disorder type I, according to DSM- IV-TR criteria. All patients were hospitalized due to worsening in symptoms, prior to inclusion. All participants were included into investigation after five days of hospital treatment. The first assessment (baseline) was made upon the inclusion. The second assessment was made after one week of continuous treatment with risperidone solution. The third assessment was made after two weeks of continuous treatment with risperidone solution. The following assessments were performed every two weeks during the period of six months. The patients who discontinued the therapy were assessed on the last day of therapy, and their results were added to the results of other patients from the group. The patients who discontinued the therapy used 8-12 mg of risperidone solution per day. After six months of continuous treatment, patients with schizophrenia scored significantly better on BPRS items regarding emotional withdrawal, conceptual disorganization, ten¬sion, uncooperativeness, hostility, hallucinatory behaviour and blunted affect. In the same time, the patients with bipolar disorder type I scored significantly better on BPRS items regarding somatic concern, anxiety, guilt feelings, grandiosity, suspiciousness, blunted effect and excitement Significant improvement was found on CGI scale in both groups of patients after six months of treatment. Treatment with risperidone solution was clinically beneficial in reducing symptoms, measured by BPRS and CGI, in the group of patients with paranoid schizophrenia and in the group of patients with bipolar disorder type I.

schizophrenia; bipolar disorder; risperidone; treatment

doi: 10.1016/j.schres.2006.01.006 ; http://dx.doi.org/10.1016/j.schres.2006.01.006